OI
SAGE

Oakbrook Investments’s Sage Therapeutics SAGE Stock Holding History

Oakbrook Investments’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,300
Closed -$207K – 647
2019
Q1 		$207K Buy
+1,300
New +$188K 0.01% 581

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Oakbrook Investments's SAGE Position: Q2 2019 in Review

Oakbrook Investments sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 1,300 shares — an estimated $207K sold.

Oakbrook Investments first reported a position in SAGE in Q1 2019 and held it in 1 quarter. The position peaked at $207K in Q1 2019. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

  • Oakbrook Investments reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Oakbrook Investments sold 1,300 Sage Therapeutics shares in Q2 2019, an estimated $207K.
  • Oakbrook Investments first reported a position in Sage Therapeutics in Q1 2019 and held it in 1 quarter.
  • Oakbrook Investments's Sage Therapeutics position peaked at $207K in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Oakbrook Investments's 13F filing for Q2 2019, filed 18 Jul 2019.